Objective: To assess specific cognitive biomarkers to increase the sensibility for the diagnosis of Prodromal Parkinson’s disease (pPD) that could help to identify these patients.

Background: pPD criteria feature a high specificity but a lack of sensitivity. Global cognitive decline is a risk marker for pPD but with low positive likelihood ratio. Thus, searching for new biomakers with a higher impact to optimize the identification of the prodromal phase of Parkinson’s disease (PD) is crucial.

Method: We evaluated a cohort of patients with pPD, PD with less than five years of disease evolution and healthy controls (HC). A detail clinical evaluation and a large neuropsychological battery were performed.  The neuropsychological assessment included Montreal Cognitive Assessment (MoCA), Parkinson`s Disease Cognitive Rating Scale (PD-CRS) and Frontal Lobe Assessment (FAB). ANOVA tests was applied to assess differences among groups and Tukey test for multiple comparisons

Results: We evaluated a cohort of patients with pPD, PD with less than five years of disease evolution and healthy controls (HC). A detail clinical evaluation and a large neuropsychological battery were performed.  The neuropsychological assessment included Montreal Cognitive Assessment (MoCA), Parkinson`s Disease Cognitive Rating Scale (PD-CRS) and Frontal Lobe Assessment (FAB). ANOVA tests was applied to assess differences among groups and Tukey test for multiple comparisons

Conclusion: In addition to global cognitive deficits, pPD patients could present with selective frontal dysfunction. Thus, frontal functioning should be deeply assessed as a putative biomarker with a higher sensitivity in prodromal phases of PD.

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/frontal-dysfunction-as-a-cognitive-biomarker-in-prodromal-parkinsons-disease/